Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03955848 | INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS(NKAML) | unknown | N/A | 80 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT03889483 | Neurophysiological Measurements Using the NeuroCatch™ Platform in Pediatric Concussion | unknown | N/A | 105 | Dr. Michael EsserOTHER | 1 | Jan 13, 2021 |
| clinicaltrials |
| NCT04707079 | A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma | unknown | Phase 2 | 24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04705090 | A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | unknown | Phase 2 | 90 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jan 12, 2021 | clinicaltrials |
| NCT04701229 | Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes(SMD-RMB22) | unknown | — | 100 | University Hospital, BrestOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT04698616 | Lean Body Mass and Side Effects in Patients With Lymphoma | unknown | — | 141 | Jens Rikardt AndersenOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT04439721 | γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse(γδT) | unknown | Early Phase 1 | 5 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04480788 | CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study | unknown | Phase 1 | 9 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04696705 | Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients | unknown | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT00498719 | Cognitive Training in Attenuating Attention Deficits/Child Treatment for Cancer | unknown | — | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT00600860 | A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes(EUMDS) | unknown | — | 4,000 | Radboud University Medical CenterOTHER | 18 | Dec 30, 2020 | clinicaltrials |
| NCT04688983 | Study in Adult Ph-positive ALL(EWALL-Ph-03) | unknown | Phase 2 | 180 | Cardiff UniversityOTHER | 0 | Dec 30, 2020 | clinicaltrials |
| NCT04665063 | A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Dec 29, 2020 | clinicaltrials |
| NCT04682314 | B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation(B-REC) | unknown | — | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Dec 23, 2020 | clinicaltrials |
| NCT03530085 | Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04679506 | the Efficacy and Safety of CLAE in R/R T-ALL/LBL | unknown | — | 50 | Peking University Third HospitalOTHER | 0 | Dec 22, 2020 | clinicaltrials |
| NCT04676789 | Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL(SPENT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04677231 | Evaluation of Long-term Health Status and Quality of Life in Adult Survivors With Philadelphia-negative Acute Lymphoblastic Leukemia/Lymphoma Treated With an Intensive Pediatric or Pediatric-inspired Protocol(EQUAALL01) | unknown | — | 300 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Dec 21, 2020 | clinicaltrials |
| NCT04254640 | Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML | unknown | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04336501 | Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation | unknown | N/A | 20 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04666168 | A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma | unknown | N/A | 200 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Dec 14, 2020 | clinicaltrials |
| NCT04665076 | Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors | unknown | N/A | 60 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Dec 11, 2020 | clinicaltrials |
| NCT03135054 | Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD | unknown | Phase 2 | 40 | The University of Hong KongOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04659434 | Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL | unknown | Phase 2 | 51 | Qian WenbinOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT04100070 | Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study(DEEP) | unknown | N/A | 320 | ISIS Diabete ServiceOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04489264 | The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma | unknown | — | 60 | Peking UniversityOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04323605 | Assistance Program for Outpatients Following an Allogeneic Hematopoietic Stem-cell Transplant(AMA-ALLO) | unknown | N/A | 50 | University Hospital, ToulouseOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04117854 | Spinal Cord Injury in the Pediatric Population - an International Multicenter Study(SINpedSCI) | unknown | — | 30 | Sunnaas Rehabilitation HospitalOTHER | 8 | Dec 2, 2020 | clinicaltrials |
| NCT04601181 | Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies | unknown | Phase 1 | 20 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Dec 1, 2020 | clinicaltrials |
| NCT03981510 | Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation | unknown | N/A | 80 | University of AarhusOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04640064 | Hb A1C Pre and Post Confinement in Latin American Children With Type 1 Diabetes: Dulce Study Group | unknown | — | 500 | Hospital General PuyoOTHER_GOV | 1 | Nov 23, 2020 | clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04638270 | Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL | unknown | Early Phase 1 | 16 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04639739 | Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. | unknown | Early Phase 1 | 9 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04025593 | Biomarker Guided Treatment in DLBCL | unknown | Phase 2 | 128 | Ruijin HospitalOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04636918 | Ikervis for DED Due to GVHD Post Allo-HSCT(Ikervis) | unknown | Phase 4 | 40 | Singapore Eye Research InstituteOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04637269 | Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma | unknown | Early Phase 1 | 16 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04516551 | Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT | unknown | Phase 1 | 18 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT04626726 | Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626739 | CAR-T Cells in Treating Patients With Relapsed or Refractory NHL | unknown | Early Phase 1 | 100 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626752 | CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626765 | CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04624893 | A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin | unknown | — | 35 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT04624971 | A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era | unknown | — | 2,000 | Sun Yat-sen UniversityOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT04622579 | Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years(R2DLBCL80) | unknown | Phase 2 | 20 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04620655 | RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL | unknown | N/A | 24 | Min XiangOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT04609150 | Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI) | unknown | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 6, 2020 | clinicaltrials |
| NCT03559439 | CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies | unknown | Phase 1 | 9 | Shanghai Tong Ren HospitalOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT00736320 | HD16 for Early Stage Hodgkin Lymphoma(HD16) | unknown | Phase 3 | 1,150 | University of CologneOTHER | 1 | Nov 4, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jan 20, 2021source: clinicaltrials